The 5 Nasdaq Stocks That Took August 2025 by Storm (And Why You Might Want to Stay Away)

by

August wasn’t just another month in the world of the Nasdaq Composite. No, this one was a bit more thrilling, and by thrilling, I mean there were some insane moves from a few select stocks that completely obliterated the index’s humble 1.6% gain. So, let’s dive into the stars of the month, because I’m sure you, like me, love watching other people make money… as long as they’re not getting away with anything illegal, right?

  1. Tharimmune (HILS): Up a whopping 378%. Oh yes, you read that correctly. If you weren’t holding this stock, I imagine the entire month must’ve been a real slap to the ego. Why the rise? Well, apparently, the biopharma company has some big news about its drug TH104, which takes aim at fentanyl. You know, just the little drug crisis that’s been ravaging the globe. Add a few patents, and voilà, you’ve got a recipe for a sizzling stock. But before you rush to get in, here’s a spoiler: Sometimes the more exciting the news, the worse the crash when reality hits. Just saying.
  2. Equillium (EQ): A nice little 345% boost. And why? Oh, nothing too dramatic. They simply raised $50 million through a private stock placement. Yes, dilution. It sounds as glamorous as a Monday morning at the office, doesn’t it? But investors are buying into the promise that the cash will push their treatment for skin and gastrointestinal diseases forward. This is one of those “we’ll see” situations. When you’re pouring money into something with *that* much risk, the glass is either half-full or half-empty-depending on which way you’re looking at it.
  3. Cognition Therapeutics (CGTX): This one saw a 315% rise after the FDA waved a flag for their Alzheimer’s drug CT1812. It’s like they threw a party and invited *everyone*. No, really, they can proceed with phase 3 testing, which is, in the world of biotech, akin to landing the lead role in a blockbuster movie. But before you start doing cartwheels, just remember: FDA approval is like a first date-it’s a great start, but there’s a long way to go before you’re making plans for the future.
  4. Professional Diversity Network (IPDN): They’re up 247%. A new CEO arrives, and bam, everything changes! Or, that’s how it looked initially. The bigger jump came when they announced a partnership that could skyrocket their growth. The moral of this story? Companies thrive on good leadership… until the new CEO starts asking too many *uncomfortable* questions about the coffee budget. So, here’s hoping it doesn’t all come crashing down if things get a little too corporate-cosy.
  5. Jyong Biotech (MENS): Ah, this one, the overachiever. A respectable 188% gain, and yet, there’s no clear reason why. The company’s mid-June IPO was like the first day at a new job: everyone’s cautiously optimistic, but no one’s sure if they’re in for a promotion or just an endless round of “get to know the team” lunches. Investors are taking a shine to its MCS-2 drug for benign prostatic hyperplasia, which is currently in phase 3 testing. Let’s just say, it’s got potential, but whether it can deliver is anyone’s guess.

Now, I know what you’re thinking. “All these stocks are doing *amazingly* well! I’m ready to dive in!” And listen, the numbers look fabulous. But let’s be real: After a 300%+ surge, jumping in now might feel a little like showing up to a party when all the good snacks are gone. There’s no shame in sitting this one out, but just make sure you’re doing your due diligence before committing your hard-earned cash. You know, just in case these stocks take the scenic route back down.

But hey, do what you will. What do I know? I’m just a seasoned investor with more than a few questionable decisions in my past. 😅

Read More

2025-09-03 14:48